3SBio inks China deal with Boston-based Verseau; Eric Topol calls for digital education in NHS report
→ China’s 3SBio has licensed rights to three immuno-oncology assets discovered by Verseau Therapeutics. Boston-based Verseau has a platform built on what it calls macrophage checkpoint modulators — monoclonal antibodies that regulate how inflammatory or tolerogenic macrophages are. In addition to taking on the development, manufacturing and commercialization of the MCMs generated in the pact, 3SBio is also participating in Verseau’s Series B with $15 million.
→ Last year, former UK health secretary Jeremy Hunt commissioned California-based Eric Topol, a cardiologist, author and digital medicine researcher, to carry out an independent review into the digital training needs of NHS staff. The report was released on Monday, detailing the promise of genomics, AI, robotics and digital medicine in the prevention, management and treatment of disease, and highlighted the importance of educating the NHS workforce of these advances.
Today, here in London, a thrill to finally hold our new report for @NHSEngland @MattHancock @DHSCgovuk. As far as I know, the 1st country to plan #healthcare w/ #AI, #genomics, digital (and to 2040!). Online, #OA tomorrow, thanks to the great work @NHS_HealthEdEng pic.twitter.com/HjxH4naYGR
— Eric Topol (@EricTopol) February 10, 2019
→ Oncology company Progenics $PGNX has acquired the Somerset, NJ-based manufacturing plant for its cancer radiation therapy Azedra for $8 million in cash. The treatment was approved last year for rare and lethal adrenal gland cancers for which there exist no approved therapies.